Imunon (IMNN) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
4 May, 2026Executive summary
Annual meeting scheduled for June 16, 2026, will be held virtually to enhance accessibility and reduce costs.
Four key proposals: election of two Class I directors, ratification of auditor, advisory vote on executive compensation, and amendment to the 2018 Stock Incentive Plan.
Record date for voting is April 17, 2026, with 3,983,342 shares outstanding.
Proxy materials and annual report are available online and by request.
Voting matters and shareholder proposals
Proposal 1: Elect two Class I Directors (Frederick J. Fritz and Christine A. Pellizzari) for terms expiring in 2029.
Proposal 2: Ratify WithumSmith + Brown PC as independent auditor for fiscal year 2026.
Proposal 3: Advisory vote to approve 2025 executive compensation.
Proposal 4: Approve amendment to 2018 Stock Incentive Plan, increasing share limit by 1,000,000 shares.
Shareholders may submit proposals for the 2027 annual meeting by specified deadlines.
Board of directors and corporate governance
Board consists of six members divided into three staggered classes; four are independent.
Committees include Audit, Compensation, Nominating and Governance, and Science and Technology.
Board diversity: 2 female, 4 male directors; all are White.
Annual review of board independence and director qualifications; stock ownership guidelines in place.
Latest events from Imunon
- Phase II survival benefit accelerates Phase III enrollment and financial improvements.IMNN
Q4 202531 Mar 2026 - IMNN-001 improved survival and surgical outcomes in advanced ovarian cancer, supporting Phase 3 plans.IMNN
Study Result2 Feb 2026 - Positive Phase II data, new funding, and reduced losses support pivotal trial plans.IMNN
Q2 20241 Feb 2026 - Phase II data show major survival gains in ovarian cancer; Phase III trial set for Q1 2025.IMNN
Q3 202415 Jan 2026 - IMNN-001 extends survival in ovarian cancer; Phase 3 starts Q1/March 2025, cash runway into Q2 2025.IMNN
Q4 202418 Dec 2025 - Shareholders will vote on director elections, share increases, a reverse split, and key governance items.IMNN
Proxy Filing2 Dec 2025 - Shareholders will vote on director elections, share increases, a reverse split, and key compensation changes.IMNN
Proxy Filing2 Dec 2025 - Highly dilutive, high-risk offering seeks up to $7.2M to fund clinical-stage immunotherapy.IMNN
Registration Filing29 Nov 2025 - Highly dilutive best-efforts IPO aims to fund clinical trials amid going concern and delisting risks.IMNN
Registration Filing29 Nov 2025